Peter Rahmer - Jan 17, 2023 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
Title: Chief Corporate Development Officer
Signature
/s/ Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Jan 17, 2023
Transactions value $
$0
Form type
4
Date filed
1/19/2023, 07:36 PM
Previous filing
Jan 5, 2023
Next filing
Jan 31, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Award $0 +97.6K +158.36% $0.00 159K Jan 17, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Award $0 +97.6K $0.00 97.6K Jan 17, 2023 Common Stock 97.6K $20.45 Direct F3
transaction RLAY Stock Option (Right to Buy) Award $0 +97.6K $0.00 97.6K Jan 17, 2023 Common Stock 97.6K $20.45 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") granted to the reporting person pursuant to the Issuer's 2020 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting.
F2 Includes 138,464 shares underlying RSUs.
F3 The shares underlying this stock option shall vest in sixteen (16) equal quarterly installments commencing on January 17, 2023, subject to the reporting person's continued service with the Issuer through each vesting date.
F4 Such option was granted pursuant to the terms of the Issuer's 2020 Stock Option and Incentive Plan and becomes exercisable, if at all, in twelve equal quarterly installments if the last quoted trading price per share of the Issuer's common stock on the Nasdaq Global Market during any fifteen consecutive calendar day period is at least $35.00; provided that the reporting person maintains a service relationship with the Issuer.

Remarks:

Title: Chief Corporate Development Officer